Albany Molecular Research (AMRI) entered into a natural products-based drug discovery collaboration with Achaogen. The deal will support Achaogen’s $24.7 million Defense Threat Reduction Agency (DTRA) contract to develop therapies to treat anthrax and other biothreat agents.
AMRI will use high-throughput screening to test samples from its natural product libraries for activity against targets of interest to Achaogen. AMRI will provide a full range of natural product-based discovery services, including fermentation, fractionation, and structure elucidation. If Achaogen chooses, AMRI may also supply follow-up services such as fermentation, optimization, scale-up, biocatalysis, and semi-synthetic chemistry.
The agreement includes an upfront payment and opportunities for AMRI to receive milestone fees based on the achievement of specific development goals. Moreover, AMRI would receive royalties on net sales.